Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
<h4>Background</h4>NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.<h4>Methods and findings</h4>The phase 2 component of our randomize...
Main Authors: | Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested, Iksung Cho, Andreana Robertson, Filip Dubovsky, Gregory M Glenn, 2019nCoV-101 Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-10-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1003769 |
Similar Items
-
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
by: Eddie Underwood, et al.
Published: (2023-12-01) -
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
by: Kirsten E. Lyke, et al.
Published: (2023-07-01) -
Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
by: Heath, PT, et al.
Published: (2021) -
Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01) -
NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
by: Carolyn Rydyznski Moderbacher, et al.
Published: (2022-10-01)